Bio-Optronics Builds Oncology-Specific Features into CTMS
Bio-Optronics has built oncology-specific function into its CTMS, Clinical Conductor
Bio-Optronics has built oncology-specific function into its CTMS, Clinical Conductor. These features include adaptive and dynamic protocol design; billing compliance function that allows organizations managing and executing oncology studies to create multiple versions of cost-allocation grids for multi-arm trials, providing more accurate billing information with less time and effort; and financial tools to accommodate complex and changing protocols, allowing organizations to effectively bill for recurring visits and other complexities that result from oncology protocol design. In addition to this, organizations can set specific Medicare coverage designations at specific sites.Finally, the CTMS contains National Cancer Institute reporting functionality that creates NCI-compliant reports and allows researchers to adhere to NCI grant requirements more easily.
Read the full release here.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
